Alpha-galactosidase A - Research Corporation Technologies
Alternative Names: Alpha-galactosidase - Research Corporation Technologies; Arginosuccinate lyase; Beta-glucosidaseLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Research Corporation Technologies
- Developer Orphan Medical; Research Corporation Technologies
- Class Enzymes; Recombinant proteins
- Mechanism of Action Alpha-galactosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fabry's disease
Most Recent Events
- 27 Nov 1998 Discontinued-Preclinical for Fabry's disease in USA (Unknown route)
- 13 May 1997 Orphan Medical is a licensee for α-galactosidase in the USA
- 13 May 1997 Preclinical development for Fabry's disease in USA (Unknown route)